Table 1.
Baseline characteristics for patients completing evaluable EORTC QLQ-C30 questionnaires
| Characteristic | Platinum–fluorouracil + cetuximab (n = 152) | Platinum–fluorouracil alone (n = 139) |
| Male, n (%) | 131 (86) | 130 (94) |
| Female, n (%) | 21 (14) | 9 (6) |
| Median age, years (range) | 56 (37–80) | 56 (33–78) |
| Karnofsky performance score, n (%) | ||
| <80 | 20 (13) | 20 (14) |
| ≥80 | 132 (87) | 119 (86) |
| Extent of disease, n (%) | ||
| Only locoregionally recurrent | 76 (50) | 70 (50) |
| Metastatic with or without locoregional recurrence | 76 (50) | 69 (50) |
| Histology, n (%) | ||
| Well/moderately differentiated | 94 (62) | 89 (64) |
| Poorly differentiated | 28 (18) | 30 (22) |
| Not specified | 28 (18) | 19 (14) |
| Missing | 2 (1) | 1 (1) |
| Disease stage, n (%) | ||
| I–III | 57 (38) | 42 (30) |
| IV | 92 (61) | 91 (65) |
| Missing | 3 (2) | 6 (4) |
| % EGFR staining, n (%) | ||
| <40 | 21 (14) | 21 (15) |
| ≥40 | 123 (81) | 107 (77) |
| Missing | 8 (5) | 11 (8) |
| Platinum therapy, n (%) | ||
| Cisplatin | 96 (63) | 86 (62) |
| Carboplatin | 55 (36) | 51 (37) |
| Missing | 1 (1) | 2 (1) |
EGFR, epidermal growth factor receptor; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30.